Patent intelligence · US
US 10696724
Activatable interleukin-2 polypeptides
Activatable interleukin-2 polypeptides
Patent details — US 10696724
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 30, 2020
- Expiration
- Jun 25, 2040
- Applicant
- Werewolf Therapeutics, Inc.
- Claims
- 11
- CPC classes
- A61K, A61K38/00, A61P, A61P35/00
Quick answer
US 10696724 (Activatable interleukin-2 polypeptides) is held by Werewolf Therapeutics, Inc.. Status: granted. Granted Jun 30, 2020. Expires Jun 25, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Werewolf Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 11
- CPC classes
- A61K, A61K38/00, A61P, A61P35/00
More from Werewolf Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12275769
Activatable interleukin 12 polypeptides and methods of use thereof
granted -
US 12076371
Activatable cytokine polypeptides and methods of use thereof
granted -
US 12036266
Activatable cytokine polypeptides and methods of use thereof
granted -
US 11981716
Activatable interleukin-2 polypeptides and methods of use thereof
granted -
US 11739132
Separation moieties and methods of use thereof
granted -
US 11535658
Activatable interleukin-2 polypeptides and methods of use thereof
granted -
US 11453710
Activatable interleukin 12 polypeptides and methods of use thereof
granted -
US 11352403
Activatable interleukin-2 polypeptides and methods of use thereof
granted
Frequently asked questions
What is US patent 10696724?
US 10696724 (Activatable interleukin-2 polypeptides) is held by Werewolf Therapeutics, Inc.. Status: granted. Granted Jun 30, 2020. Expires Jun 25, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10696724?
Werewolf Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 10 pharmaceutical patents for this assignee.
When does US 10696724 expire?
Our index shows an expiration date of Jun 25, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.